PTC THERAPEUTICS INC (PTCT) Stock Fundamental Analysis
USA - NASDAQ:PTCT - US69366J2006 - Common Stock
73.08 USD
+0.6 (+0.83%)
Overall PTCT gets a fundamental rating of 5 out of 10. We evaluated PTCT against 531 industry peers in the Biotechnology industry. PTCT has only an average score on both its financial health and profitability. PTCT is growing strongly while it is still valued neutral. This is a good combination! These ratings would make PTCT suitable for growth investing!
1. Profitability
1.1 Basic Checks
PTCT had positive earnings in the past year.
In the past year PTCT had a positive cash flow from operations.
PTCT had negative earnings in each of the past 5 years.
PTCT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
PTCT's Return On Assets of 28.43% is amongst the best of the industry. PTCT outperforms 98.12% of its industry peers.
PTCT has a better Return On Invested Capital (41.48%) than 99.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.43% | ||
| ROE | N/A | ||
| ROIC | 41.48% |
ROA(3y)-29.05%
ROA(5y)-26.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PTCT has a Profit Margin of 42.25%. This is amongst the best in the industry. PTCT outperforms 97.93% of its industry peers.
PTCT's Operating Margin of 52.45% is amongst the best of the industry. PTCT outperforms 99.62% of its industry peers.
Looking at the Gross Margin, with a value of 96.83%, PTCT belongs to the top of the industry, outperforming 96.05% of the companies in the same industry.
PTCT's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 52.45% | ||
| PM (TTM) | 42.25% | ||
| GM | 96.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y-0.66%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so PTCT is creating value.
PTCT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PTCT has been increased compared to 5 years ago.
The debt/assets ratio for PTCT is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.09 indicates that PTCT is not a great score, but indicates only limited risk for bankruptcy at the moment.
PTCT has a better Altman-Z score (2.09) than 67.23% of its industry peers.
PTCT has a debt to FCF ratio of 3.38. This is a good value and a sign of high solvency as PTCT would need 3.38 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.38, PTCT belongs to the top of the industry, outperforming 93.03% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.38 | ||
| Altman-Z | 2.09 |
ROIC/WACC5.84
WACC7.1%
2.3 Liquidity
A Current Ratio of 2.32 indicates that PTCT has no problem at all paying its short term obligations.
PTCT has a Current ratio of 2.32. This is in the lower half of the industry: PTCT underperforms 70.62% of its industry peers.
PTCT has a Quick Ratio of 2.26. This indicates that PTCT is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of PTCT (2.26) is worse than 69.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.32 | ||
| Quick Ratio | 2.26 |
3. Growth
3.1 Past
PTCT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 277.07%, which is quite impressive.
The Revenue has grown by 97.54% in the past year. This is a very strong growth!
Measured over the past years, PTCT shows a very strong growth in Revenue. The Revenue has been growing by 21.32% on average per year.
EPS 1Y (TTM)277.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.39%
Revenue 1Y (TTM)97.54%
Revenue growth 3Y14.42%
Revenue growth 5Y21.32%
Sales Q2Q%7.23%
3.2 Future
PTCT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.77% yearly.
PTCT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.87% yearly.
EPS Next Y225.38%
EPS Next 2Y19.18%
EPS Next 3Y23.42%
EPS Next 5Y19.77%
Revenue Next Year113.44%
Revenue Next 2Y3.3%
Revenue Next 3Y9.97%
Revenue Next 5Y16.87%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 10.07, which indicates a very decent valuation of PTCT.
Based on the Price/Earnings ratio, PTCT is valued cheaply inside the industry as 97.55% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of PTCT to the average of the S&P500 Index (26.28), we can say PTCT is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for PTCT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.07 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PTCT is valued cheaper than 98.31% of the companies in the same industry.
PTCT's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PTCT is cheaper than 98.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.23 | ||
| EV/EBITDA | 5.63 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as PTCT's earnings are expected to grow with 23.42% in the coming years.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y19.18%
EPS Next 3Y23.42%
5. Dividend
5.1 Amount
No dividends for PTCT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:PTCT (11/11/2025, 11:43:36 AM)
73.08
+0.6 (+0.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners101.79%
Inst Owner Change-5.57%
Ins Owners0.7%
Ins Owner Change3.44%
Market Cap5.81B
Revenue(TTM)1.78B
Net Income(TTM)751.72M
Analysts78.26
Price Target69.63 (-4.72%)
Short Float %10.09%
Short Ratio6.3
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)68.83%
Min EPS beat(2)23.33%
Max EPS beat(2)114.33%
EPS beat(4)3
Avg EPS beat(4)1164.83%
Min EPS beat(4)-221.32%
Max EPS beat(4)4742.99%
EPS beat(8)5
Avg EPS beat(8)562.98%
EPS beat(12)5
Avg EPS beat(12)357.38%
EPS beat(16)5
Avg EPS beat(16)260.9%
Revenue beat(2)2
Avg Revenue beat(2)7.12%
Min Revenue beat(2)2.58%
Max Revenue beat(2)11.67%
Revenue beat(4)3
Avg Revenue beat(4)147.37%
Min Revenue beat(4)-10.09%
Max Revenue beat(4)585.33%
Revenue beat(8)5
Avg Revenue beat(8)76.88%
Revenue beat(12)7
Avg Revenue beat(12)50.21%
Revenue beat(16)10
Avg Revenue beat(16)38.94%
PT rev (1m)2.5%
PT rev (3m)2.09%
EPS NQ rev (1m)-0.89%
EPS NQ rev (3m)-29.32%
EPS NY rev (1m)-0.96%
EPS NY rev (3m)8.95%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)-1.43%
Revenue NY rev (1m)-0.56%
Revenue NY rev (3m)-0.62%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.07 | ||
| Fwd PE | N/A | ||
| P/S | 3.26 | ||
| P/FCF | 8.23 | ||
| P/OCF | 8.11 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.63 |
EPS(TTM)7.26
EY9.93%
EPS(NY)-3.48
Fwd EYN/A
FCF(TTM)8.88
FCFY12.15%
OCF(TTM)9.01
OCFY12.32%
SpS22.4
BVpS-1.96
TBVpS-7.99
PEG (NY)0.04
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.43% | ||
| ROE | N/A | ||
| ROCE | 52.5% | ||
| ROIC | 41.48% | ||
| ROICexc | 822.48% | ||
| ROICexgc | N/A | ||
| OM | 52.45% | ||
| PM (TTM) | 42.25% | ||
| GM | 96.83% | ||
| FCFM | 39.64% |
ROA(3y)-29.05%
ROA(5y)-26.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y-0.66%
F-Score7
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.38 | ||
| Debt/EBITDA | 1.9 | ||
| Cap/Depr | 31.38% | ||
| Cap/Sales | 0.58% | ||
| Interest Coverage | 163.67 | ||
| Cash Conversion | 74.07% | ||
| Profit Quality | 93.81% | ||
| Current Ratio | 2.32 | ||
| Quick Ratio | 2.26 | ||
| Altman-Z | 2.09 |
F-Score7
WACC7.1%
ROIC/WACC5.84
Cap/Depr(3y)15.16%
Cap/Depr(5y)26.1%
Cap/Sales(3y)2.81%
Cap/Sales(5y)3.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)277.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.39%
EPS Next Y225.38%
EPS Next 2Y19.18%
EPS Next 3Y23.42%
EPS Next 5Y19.77%
Revenue 1Y (TTM)97.54%
Revenue growth 3Y14.42%
Revenue growth 5Y21.32%
Sales Q2Q%7.23%
Revenue Next Year113.44%
Revenue Next 2Y3.3%
Revenue Next 3Y9.97%
Revenue Next 5Y16.87%
EBIT growth 1Y813.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year735.42%
EBIT Next 3Y50.48%
EBIT Next 5YN/A
FCF growth 1Y375.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y419.28%
OCF growth 3YN/A
OCF growth 5YN/A
PTC THERAPEUTICS INC / PTCT FAQ
What is the ChartMill fundamental rating of PTC THERAPEUTICS INC (PTCT) stock?
ChartMill assigns a fundamental rating of 5 / 10 to PTCT.
Can you provide the valuation status for PTC THERAPEUTICS INC?
ChartMill assigns a valuation rating of 6 / 10 to PTC THERAPEUTICS INC (PTCT). This can be considered as Fairly Valued.
Can you provide the profitability details for PTC THERAPEUTICS INC?
PTC THERAPEUTICS INC (PTCT) has a profitability rating of 5 / 10.
What are the PE and PB ratios of PTC THERAPEUTICS INC (PTCT) stock?
The Price/Earnings (PE) ratio for PTC THERAPEUTICS INC (PTCT) is 10.07 and the Price/Book (PB) ratio is -37.27.